Acetyl-L-carnitine and Amyotrophic Lateral Sclerosis: Current Evidence and Potential use.

IF 2.7 4区医学 Q3 NEUROSCIENCES

CNS & neurological disorders drug targets Pub Date : 2024-01-01 DOI:10.2174/1871527322666230330083757

Fabiola De Marchi, Sakthipriyan Venkatesan, Massimo Saraceno, Letizia Mazzini, Elena Grossini

{"title":"Acetyl-L-carnitine and Amyotrophic Lateral Sclerosis: Current Evidence and Potential use.","authors":"Fabiola De Marchi, Sakthipriyan Venkatesan, Massimo Saraceno, Letizia Mazzini, Elena Grossini","doi":"10.2174/1871527322666230330083757","DOIUrl":null,"url":null,"abstract":"Background: The management of neurodegenerative diseases can be frustrating for clinicians, given the limited progress of conventional medicine in this context.Aim: For this reason, a more comprehensive, integrative approach is urgently needed. Among various emerging focuses for intervention, the modulation of central nervous system energetics, oxidative stress, and inflammation is becoming more and more promising.Methods: In particular, electrons leakage involved in the mitochondrial energetics can generate reactive oxygen-free radical-related mitochondrial dysfunction that would contribute to the etiopathology of many disorders, such as Alzheimer's and other dementias, Parkinson's disease, multiple sclerosis, stroke, and amyotrophic lateral sclerosis (ALS).Results: In this context, using agents, like acetyl L-carnitine (ALCAR), provides mitochondrial support, reduces oxidative stress, and improves synaptic transmission.Conclusion: This narrative review aims to update the existing literature on ALCAR molecular profile, tolerability, and translational clinical potential use in neurodegeneration, focusing on ALS.","PeriodicalId":10456,"journal":{"name":"CNS & neurological disorders drug targets","volume":" ","pages":"588-601"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS & neurological disorders drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1871527322666230330083757","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The management of neurodegenerative diseases can be frustrating for clinicians, given the limited progress of conventional medicine in this context.

Aim: For this reason, a more comprehensive, integrative approach is urgently needed. Among various emerging focuses for intervention, the modulation of central nervous system energetics, oxidative stress, and inflammation is becoming more and more promising.

Methods: In particular, electrons leakage involved in the mitochondrial energetics can generate reactive oxygen-free radical-related mitochondrial dysfunction that would contribute to the etiopathology of many disorders, such as Alzheimer's and other dementias, Parkinson's disease, multiple sclerosis, stroke, and amyotrophic lateral sclerosis (ALS).

Results: In this context, using agents, like acetyl L-carnitine (ALCAR), provides mitochondrial support, reduces oxidative stress, and improves synaptic transmission.

Conclusion: This narrative review aims to update the existing literature on ALCAR molecular profile, tolerability, and translational clinical potential use in neurodegeneration, focusing on ALS.

查看原文本刊更多论文

乙酰基-L-肉碱与肌萎缩侧索硬化症：当前证据和潜在用途。

背景：目的：因此，迫切需要一种更全面的综合方法。在各种新出现的干预重点中，调节中枢神经系统的能量、氧化应激和炎症正变得越来越有前景：方法：线粒体能量所涉及的电子泄漏尤其会产生与活性氧自由基相关的线粒体功能障碍，从而导致许多疾病的病因，如阿尔茨海默氏症和其他痴呆症、帕金森氏症、多发性硬化症、中风和肌萎缩性脊髓侧索硬化症（ALS）：在这种情况下，使用乙酰左旋肉碱（ALCAR）等药物可为线粒体提供支持，减少氧化应激，改善突触传递：本综述旨在更新有关 ALCAR 分子特征、耐受性以及在神经退行性病变中的临床转化应用潜力的现有文献，重点关注 ALS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CNS & neurological disorders drug targets 医学-神经科学

CiteScore

5.10

自引率

3.30%

发文量

158

审稿时长

6-12 weeks

期刊介绍： Aims & Scope CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. CNS & Neurological Disorders - Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.